Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

NCT06951971 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hemophagocytic Lymphohistiocytosis (HLH)

Interventions

DRUG: dose-modified E-Ru
OTHER: Salvage treatment and follow-up

Sponsor

The First Affiliated Hospital of Soochow University